Fagron NV (ARSUF) Q3 2026 Sales/Trading Call Transcript

SA Transcripts 162.43K Followers Follow Fagron NV ( ARSUF ) Q3 2026 Sales/Trading Call October 8, 2026 3:30 AM EDT Company Participants Ignacio Artola - Global Head of Investor Relations Rafael Padilla - CEO & Executive Director Karin de Jong - CFO & Executive Director Conference Call Participants Stijn Demeester - ING Groep N.V., Research Division Frank Claassen - Banque Degroof Petercam S.A., Research Division Michael Heider - Joh. Berenberg, Gossler & Co. KG, Research Division Eric Wilmer - Kempen & Co. N.V., Research Division Presentation Ignacio Artola Global Head of Investor Relations Hello, and good morning, everyone. Welcome to Fagron's Q3 2026 Trading Statement Webcast. I am joined today by our CEO, Rafael Padilla; and our CFO, Karin de Jong. We will start by discussing the company's performance and a closer look at regional developments. And afterwards, we will open the floor for questions. With that, I will hand over to Rafael. Rafael Padilla CEO & Executive Director Thanks, Ignacio, and good morning all. We're pleased to report another quarter of growth. Revenue reached EUR 281.3 million, up 23.2% or 19.5% at constant exchange rates. Organic growth was -- at CER was 3.4%. Performance was led by EMEA and Latin America, together with Brands and Essentials in North America, which grew 26.1% organically. Our acquisitions also made a strong contribution. In North America, Compounding Services was impacted by the third-party industry-wide IV bag recall earlier in the year. Supply has now stabilized, and we expect volumes to recover progressively through the fourth quarter. During the quarter, we completed the acquisition of Injeplast in Brazil. This means all previously announced acquisitions are now closed and integration is on track. Finally, we're confirming our full year outlook to revenue of EUR 1.125 billion to EUR 1.150 billion with an adjusted EBITDA margin of 19.5% to 20%. Let's now look at the regions. In